NCT05474027

Brief Summary

This prospective study will analyze the need for deliberate hypotensive anesthesia (DHA) during orthognathic surgery when tranexamic acid (TXA) is administered. DHA has been proven to be effective although it comes with multiple risks related to organ hypoperfusion including kidney injury, stroke, and cardiac ischemia. Therefore, it may be potentially safer for patients to avoid deliberate hypotensive anesthesia if TXA alone adequately controls blood loss and provides adequate surgical site visualization.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2022

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 26, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

November 11, 2022

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

December 19, 2024

Status Verified

December 1, 2024

Enrollment Period

3.1 years

First QC Date

July 20, 2022

Last Update Submit

December 16, 2024

Conditions

Keywords

orthognathic surgery

Outcome Measures

Primary Outcomes (3)

  • Surgeon's Analysis of Surgical Field Visualization

    The surgeon will evaluate surgical field visibility using Fromme's ordinal scale

    1 year

  • Mean Arterial Pressure

    Tracking mean arterial pressures throughout surgery, evaluating if patient's blood pressure can be reliably kept around patient's baseline instead of deliberate hypotensive anesthesia.

    1 year

  • Estimated Blood Loss

    Volume of blood loss recorded during surgical case

    1 year

Study Arms (1)

Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia

EXPERIMENTAL
Other: Avoidance of Deliberate Hypotensive AnesthesiaDrug: TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION

Interventions

The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.

Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia

1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.

Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia

Eligibility Criteria

Age12 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Bimaxillary orthognathic surgery completed at UAB Highlands Hospital

You may not qualify if:

  • History of hypertension or previously diagnosed cardiac problems
  • Bleeding diathesis
  • TXA medically contraindicated

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UAB Hospital-Highlands

Birmingham, Alabama, 35205, United States

Location

MeSH Terms

Conditions

Blood Loss, Surgical

Interventions

Tranexamic AcidInjections, IntravenousSolutions

Condition Hierarchy (Ancestors)

HemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsIntraoperative Complications

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAdministration, IntravenousDrug Administration RoutesDrug TherapyTherapeuticsInjectionsPharmaceutical Preparations

Study Officials

  • Brian Kinard, DMD, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Our goal is to enroll 50 patients. Patients will be recruited from Dr. Kinard's regularly scheduled orthognathic cases at UAB Highlands Hospital. The patient will be informed of the study in advance and have consent signed pre-operatively. 1g of tranexamic acid will be given perioperatively as already routinely performed. The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to patient baseline.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 20, 2022

First Posted

July 26, 2022

Study Start

November 11, 2022

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

December 19, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations